AIM ImmunoTech (AIM) Registration Filing summary

Offering details and pricing

• Rights offering of up to 12,000 units, each unit includes one share of Series G Convertible Preferred Stock and 1,666 Class G Common Stock Purchase Warrants, at $1,000 per unit, with a subscription period from February 11 to February 27, 2026, extendable by up to 60 days.

• Each share of Series G Preferred Stock is convertible into common stock at a conversion price to be set, and each warrant is exercisable for one share of common stock at an exercise price to be set, expiring five years from issuance.

• Subscription rights are non-transferable and distributed to holders of record as of February 4, 2026, with an over-subscription privilege for holders who fully exercise their basic rights, subject to a 19.99% ownership cap.

• If demand exceeds supply, units are allocated pro rata among exercising holders; excess payments are returned without interest.

Use of proceeds and capital allocation

• Net proceeds from the rights offering will be used as described in the prospectus under "Use of Proceeds."

Underwriters and syndicate

• Maxim Group LLC is the exclusive dealer-manager for the rights offering, receiving an 8% cash fee on gross proceeds and up to $125,000 for fees and expenses.

• Broadridge Corporate Issuer Solutions, LLC acts as subscription and information agent; Equiniti Trust Company, LLC is the warrant agent.